On February 17, 2023, Apellis announced the FDA approval of Pegcetacoplan, a complement C3 inhibitor, as the first molecularly targeted drug for the treatment of dry AMD or geographic atrophy. This approvalRead More…
On February 16, Iveric Bio announced in an announcement that the New Drug Application (NDA) for the complement C5 inhibitor Zimura (avacincaptad pegol, ACP) for the treatment of age-related macular degeneration (AMD)Read More…
On November 3, 2022, Iveric Bio announced that it had submitted the first part of the “rolling review” for the new drug application (NDA) of avacincaptad pegol (ACP, also known as Zimura)Read More…
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…